What is Supernus Pharmaceuticals's market cap?

Supernus Pharmaceuticals (SUPN) has a market capitalization of $2.7B and trades on NASDAQ.

What is Supernus Pharmaceuticals's revenue and profitability?

Supernus Pharmaceuticals generated $776.8M in trailing twelve-month revenue with a net loss of $29.0M, representing a net margin of -3.7%. Gross margin stands at 89.4%, with free cash flow of $174.3M. These figures are based on the Q1 2026 filing.

Who are Supernus Pharmaceuticals's competitors?

Supernus Pharmaceuticals's key competitors include Lipocine, Inc., Vanda Pharmaceuticals Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does Supernus Pharmaceuticals partner with?

Supernus Pharmaceuticals's notable partners include Biogen MA Inc., Shionogi & Co., Ltd., Britannia Pharmaceuticals, and others.

What subsidiaries does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals's subsidiaries include Sage Therapeutics, LLC.

Where is Supernus Pharmaceuticals headquartered?

Supernus Pharmaceuticals is headquartered in United States of America and employs approximately 652 people. It has been publicly traded since 2012.

Supernus Pharmaceuticals

SUPN

Supernus Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of products for central nervous system (CNS) diseases.

Market cap

$2.73B+45.1%

Revenue$776.8M+16.3%

Net income-$29.0M-147%

Free cash flow$174.3M+1.8%

EPS (diluted)-$0.51-146%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$207.7MBeat by $14.8M EPS$0.59Beat by $0.31

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$205.3M

EPS estimate$0.42

Financials

Q1 2026

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation & ratios

Valuation

See full

Market cap$2.73B+45.1%

Enterprise value$2.58B+46.9%

P/S3.5×+0.7×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Segments

By product

See full

Qelbree$77.8M+20.2%

GOCOVRI$35.2M+14.8%

Royalty, licensing, and other revenues$29.3M+274%

Collaboration revenue (ZURZUVAE)$27.6M—

Trokendi XR$9.5M-26.0%

By segment

See full

Reportable Segment$207.7M+38.6%

Competitors

By market cap

AbbVie$453.91B+36.3%

Neurocrine Biosciences$17.7B+34.0%

Axsome Therapeutics$12.3B+148%

Acadia Pharmaceuticals$4.3B+14.8%

Supernus Pharmaceuticals$2.7B+45.8%

Vanda Pharmaceuticals$313.9M+13.3%

Minerva Neurosciences$195.9M+1,234%

Lipocine$17.6M-2.9%

By revenue growth

Axsome Therapeutics+63.9%

Neurocrine Biosciences+28.6%

Supernus Pharmaceuticals+16.3%

Acadia Pharmaceuticals+9.9%

AbbVie+9.5%

By net margin

Acadia Pharmaceuticals34.3%+11.3pp

Neurocrine Biosciences21.55%+8.9pp

AbbVie5.79%-1.5pp

Supernus Pharmaceuticals-3.74%-13.0pp

Axsome Therapeutics-26.59%+37.8pp

Profile

Supernus Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of products for central nervous system (CNS) diseases. The company maintains a diverse neuroscience portfolio addressing conditions such as ADHD, Parkinson's disease, epilepsy, migraine, and postpartum depression. Its value proposition centers on leveraging proprietary drug delivery technologies and strategic acquisitions to improve patient outcomes in neurology and psychiatry.

Competitive position

Supernus is a leading player in the CNS specialty pharmaceutical market, distinguished by its focus on non-stimulant ADHD options and specialized Parkinson's motor complication treatments.

GeographiesUnited States, Japan, Canada, Europe

Customer segmentsPharmaceutical Wholesalers, Specialty Pharmacies, Healthcare Providers

Business modelResearch and Development, Product Commercialization, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Raw material suppliers in Asia and Europe, Third-party logistics providers

CustomersCencora, Inc., Cardinal Health, Inc., McKesson Corporation, Specialty pharmacies, Hospitals

CountryUnited States of America

Listed2012

Employees652.0

CEOJack A. Khattar

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitesupernus.com

FilingsSEC EDGAR

Ask your AI about Supernus Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's market cap?: Supernus Pharmaceuticals (SUPN) has a market capitalization of $2.7B and trades on NASDAQ.
What is Supernus Pharmaceuticals's revenue and profitability?: Supernus Pharmaceuticals generated $776.8M in trailing twelve-month revenue with a net loss of $29.0M, representing a net margin of -3.7%. Gross margin stands at 89.4%, with free cash flow of $174.3M. These figures are based on the Q1 2026 filing.
Who are Supernus Pharmaceuticals's competitors?: Supernus Pharmaceuticals's key competitors include Lipocine, Inc., Vanda Pharmaceuticals Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does Supernus Pharmaceuticals partner with?: Supernus Pharmaceuticals's notable partners include Biogen MA Inc., Shionogi & Co., Ltd., Britannia Pharmaceuticals, and others.
What subsidiaries does Supernus Pharmaceuticals have?: Supernus Pharmaceuticals's subsidiaries include Sage Therapeutics, LLC.
Where is Supernus Pharmaceuticals headquartered?: Supernus Pharmaceuticals is headquartered in United States of America and employs approximately 652 people. It has been publicly traded since 2012.